Zanen P - Search Results

1

Methotrexate vs azathioprine in second-line therapy of sarcoidosis.

Vorselaars ADM, Wuyts WA, Vorselaars VMM, Zanen P, Deneer VHM, Veltkamp M, Thomeer M, van Moorsel CHM, Grutters JC. Vorselaars ADM, et al. Among authors: zanen p. Chest. 2013 Sep;144(3):805-812. doi: 10.1378/chest.12-1728. Chest. 2013. PMID: 23538719

2

ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy.

Vorselaars AD, van Moorsel CH, Zanen P, Ruven HJ, Claessen AM, van Velzen-Blad H, Grutters JC. Vorselaars AD, et al. Among authors: zanen p. Respir Med. 2015 Feb;109(2):279-85. doi: 10.1016/j.rmed.2014.11.009. Epub 2014 Nov 29. Respir Med. 2015. PMID: 25496652 Free article.

3

Telomere length in interstitial lung diseases.

Snetselaar R, van Moorsel CHM, Kazemier KM, van der Vis JJ, Zanen P, van Oosterhout MFM, Grutters JC. Snetselaar R, et al. Among authors: zanen p. Chest. 2015 Oct;148(4):1011-1018. doi: 10.1378/chest.14-3078. Chest. 2015. PMID: 25973743

4

Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.

van der Lee I, Zanen P, Grutters JC, Snijder RJ, van den Bosch JMM. van der Lee I, et al. Among authors: zanen p. Chest. 2006 Feb;129(2):378-383. doi: 10.1378/chest.129.2.378. Chest. 2006. PMID: 16478855

5

Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis.

Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC. Moll SA, et al. Among authors: zanen p. Biomark Med. 2020 Jul;14(11):997-1007. doi: 10.2217/bmm-2020-0165. Biomark Med. 2020. PMID: 32940077

6

Long-term Clinical Outcome of Antibody Replacement Therapy in Humoral Immunodeficient Adults With Respiratory Tract Infections.

van Kessel DA, Hoffman TW, van Velzen-Blad H, Zanen P, Grutters JC, Rijkers GT. van Kessel DA, et al. Among authors: zanen p. EBioMedicine. 2017 Apr;18:254-260. doi: 10.1016/j.ebiom.2017.03.025. Epub 2017 Mar 21. EBioMedicine. 2017. PMID: 28347655 Free PMC article.

7

Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis.

Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Barlo NP, et al. Among authors: zanen p. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):155-61. Sarcoidosis Vasc Diffuse Lung Dis. 2009. PMID: 20560296

8

18F-FDG PET as a predictor of pulmonary function in sarcoidosis.

Keijsers RG, Verzijlbergen EJ, van den Bosch JM, Zanen P, van de Garde EM, Oyen WJ, Grutters JC. Keijsers RG, et al. Among authors: zanen p. Sarcoidosis Vasc Diffuse Lung Dis. 2011 Oct;28(2):123-9. Sarcoidosis Vasc Diffuse Lung Dis. 2011. PMID: 22117503

9

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes.

Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Zanen P, Wijsenbeek MS, Eijkemans MJC, Biesma DH, van der Wees PJ, Grutters JC. Kampstra NA, et al. Among authors: zanen p. ERJ Open Res. 2019 Oct 30;5(4):00094-2019. doi: 10.1183/23120541.00094-2019. eCollection 2019 Oct. ERJ Open Res. 2019. PMID: 31687368 Free PMC article.

10

Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias.

Korthagen NM, van Moorsel CH, Zanen P, Ruven HJ, Grutters JC. Korthagen NM, et al. Among authors: zanen p. Lung. 2014 Dec;192(6):975-80. doi: 10.1007/s00408-014-9647-9. Epub 2014 Oct 2. Lung. 2014. PMID: 25274153

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page